Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes

INTRODUCTION: The BCL-2 inhibitor venetoclax has been widely used in the treatment of acute myeloid leukemia (AML); however, AML patients treated with venetoclax gradually develop resistance. The exportin-1 (XPO1) inhibitor selinexor can synergistically promote the antileukemia activity of venetocla...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jiqian, Wang, Yan, Liu, Dan, Wang, Xiaoyu, Zhu, Yingqiao, Tong, Juan, Chen, Erling, Xue, Lei, Zhao, Na, Liang, Tingting, Zheng, Changcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680489/
https://www.ncbi.nlm.nih.gov/pubmed/38026089
http://dx.doi.org/10.2147/ITT.S429402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680489/
https://www.ncbi.nlm.nih.gov/pubmed/38026089
http://dx.doi.org/10.2147/ITT.S429402

Ejemplares similares